"First-line therapy with the bispecific antibody pumitamig was associated with “encouraging” overall response rates in both squamous cell and nonsquamous NSCLC regardless of PD-L1 expression levels, according to dose-optimization findings from the ROSETTA Lung-02 trial.3\n\n“This is the first global data for specifically an anti-PD-L1 VEGFA bispecific antibody in frontline metastatic non-small cell lung cancer, in addition to chemotherapy,” reported study coauthor Solange Peters, MD, PhD, of Lausanne University in Switzerland. Encouraging response rates were seen across histology and PD-L1 levels, along with a manageable safety profile and no new safety signals, she said.\n\nPumitamig reverses tumors’ immunosuppression of immune T-cells with PD-L1 checkpoint blockade within the tumor microenvironment and neutralizes VEGFA normalization of tumor vasculature, Dr Peters explained."